title: ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis.
abstract: OBJECTIVE
  To evaluate various validity aspects of four disease activity scores (ASDAS) for ankylosing spondylitis (AS) in comparison with the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), its individual components and physician and patient global assessment of disease activity.
  
  
  METHODS
  The analyses were performed in two cohorts of patients with AS: (1) the NOR-DMARD database which includes patients starting on a disease-modifying antirheumatic drug or tumour necrosis factor (TNF) blocker and (2) patients participating in double-blind placebo controlled randomised clinical trials with TNF blockers in four centres. Discrimination between patients with low versus high disease activity according to various definitions and between various levels of change were analysed as the standardised mean difference (difference in the group means divided by the pooled SD of the group means) and t score.
  
  
  RESULTS
  The four ASDAS versions were highly discriminatory in differentiating patients with different levels of disease activity and patients with different levels of change. The ASDAS scores outperformed the BASDAI and its single components in all settings: patient- or physician-based, reflecting status or change, with normal or raised C-reactive protein (CRP), in the presence or absence of peripheral arthritis. There were no major differences between the four ASDAS scores. Based on feasibility, the ASAS membership selected the ASDAS version which included back pain, duration of morning stiffness, patient global assessment, peripheral joint complaints and CRP as the preferred version.
  
  
  CONCLUSIONS
  The ASDAS is a validated, highly discriminatory instrument for assessing disease activity in AS, including patient-reported outcomes and CRP levels.
authors.affiliation: Department of Rheumatology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands. d.vanderheijde@kpnplanet.nl
authors.forename: D
authors.initials: D
authors.lastname: van der Heijde
authors.forename: E
authors.initials: E
authors.lastname: Lie
authors.forename: T K
authors.initials: TK
authors.lastname: Kvien
authors.forename: J
authors.initials: J
authors.lastname: Sieper
authors.forename: F
authors.initials: F
authors.lastname: Van den Bosch
authors.forename: J
authors.initials: J
authors.lastname: Listing
authors.forename: J
authors.initials: J
authors.lastname: Braun
authors.forename: R
authors.initials: R
authors.lastname: Landewé
mesh_terms: D000328:Adult; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001416:Back Pain / Q000209:etiology; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000032:analysis; D004812:Epidemiologic Methods; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012720:Severity of Illness Index; D013167:Spondylitis, Ankylosing / Q000150:complications / Q000188:drug therapy*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D018501:Antirheumatic Agents; D015415:Biomarkers; D014409:Tumor Necrosis Factor-alpha; D002097:C-Reactive Protein